Opus Genetics president Ben Yerxa (L) and CEO George Magrath
October 22, 2024 04:05 PM EDT
Startups
Deals
Cell/Gene Tx

Eye drop mak­er to merge with a reti­nal gene ther­a­py start­up from Spark co-founder

Kyle LaHucik

Senior Reporter

The eye drop mak­er Ocuphire Phar­ma and start­up Opus Ge­net­ics are merg­ing in an all-stock deal, the com­pa­nies told End­points News.

Ocuphire $OCUP will ac­quire …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Ahead of No­vo’s Ca­griSe­ma read­out, Lil­ly re­turns to a promis­ing new class of obe­si­ty drugs

Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Roche, Genen­tech end an­ti-tau Alzheimer’s drug col­lab­o­ra­tion with UCB

Be Bio rais­es $82M to fund work on B cell ther­a­py in he­mo­phil­ia B

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times